Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
“That's a lot. That is a lot… Now, just understand that, yeah, they are milestone payments, not actual. Now, here's what you have to understand. I have always felt that if you have something that is for cancer and it works, then you have to own the stock as a speculation, but just as a speculation, because it's been such a difficult disease. J&J and Merck are the ones that are ahead if you want the majors.” Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels Kura Oncology, Inc. (NASDAQ:KURA) is developing targeted cancer therapies focused on genetically defined leukemias and solid tumors, with several drug candidates in clinical development. In November, the company, along with Kyowa Kirin received FDA approval for KOMZIFTI (ziftomenib), a once-daily oral targeted therapy for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. On December 8, Kura Oncology and Kyowa Kirin reported early trial results showing that KOMZIFTI com
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]Yahoo! Finance
- Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]CNBC
- Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AMLGlobeNewswire
- Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]Yahoo! Finance
- Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 144
- 12/10/25 - Form 4
- KURA's page on the SEC website